The kynurenine 3-hydroxylase inhibitor Ro 61-8048 improves dystonia in a genetic model of paroxysmal dyskinesia

Publisher： Elsevier

ISSN： 0014-2999

Source： European Journal of Pharmacology, Vol.478, Iss.1, 2003-09, pp. : 47-52

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Effects of pharmacological manipulations of cannabinoid receptors on severity of dystonia in a genetic model of paroxysmal dyskinesia

By Richter A. Loscher W.

European Journal of Pharmacology, Vol. 454, Iss. 2, 2002-11 ,pp. : 145-151

Elsevier

Access to resources Recommend Favorite

CGS 21680 exerts marked antidystonic effects in a genetic model of paroxysmal dyskinesia

By Richter A. Hamann M. Bartling C.

European Journal of Pharmacology, Vol. 404, Iss. 3, 2000-09 ,pp. : 299-302

Elsevier

Access to resources Recommend Favorite

Paradoxical aggravation of paroxysmal dystonia during chronic treatment with phenobarbital in a genetic rodent model

By Richter A. Loscher W.

European Journal of Pharmacology, Vol. 397, Iss. 2, 2000-06 ,pp. : 343-350

Elsevier

Access to resources Recommend Favorite

Gabapentin decreases the severity of dystonia at low doses in a genetic animal model of paroxysmal dystonic choreoathetosis

By Richter A. Loscher W.

European Journal of Pharmacology, Vol. 369, Iss. 3, 1999-03 ,pp. : 335-338

Elsevier

Access to resources Recommend Favorite

The NMDA receptor NR2B subtype selective antagonist Ro 25-6981 aggravates paroxysmal dyskinesia in the dt sz mutant

By Richter A.

European Journal of Pharmacology, Vol. 458, Iss. 1, 2003-01 ,pp. : 107-110

Elsevier

Access to resources Recommend Favorite